tapentadol (CG5503) ER 50-mg TRF

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Healthy Volunteer

Phase 1

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

CompletedNCT01273506

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy Volunteer

Start: 2010-12-31End: 2011-02-28Updated: 2012-03-13

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet

CompletedNCT01273532

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy Volunteer

Start: 2010-12-31End: 2011-03-31Updated: 2012-03-13

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

CompletedNCT01309425

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy Volunteer

Start: 2011-02-28End: 2011-05-31Updated: 2014-01-31